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Introduction
Chagas disease, caused by the protozoan Trypanosoma cruzi, remains one of the most important causes of cardiac related mortality and disability in endemic areas. According to the latest WHO report, 6 million people are affected in Latin America. However, due to immigration processes, the disease is extending its distribution towards non-endemic areas such as the US and some European countries 1 . Chronic Chagas heart disease (CCHD) constitutes its most frequent and serious presentation, developing in approximately 30% of infected non-treated individuals. In advanced stages, it comprises different kinds of manifestations including dilated cardiomyopathy with heart failure (HF), arrhythmias, heart blocks and even sudden death 2 
.
Although it has been widely disclosed that inflammatory response plays a major role in CCHD, humoral autoimmune response seems to be related to clinical progression of these patients. Several authors have identified molecular mimicry between some parasitic and host's proteins. This mechanism originates some cross-reacting IgG as anti-B13, anti-p2β and anti-β1AR (β1 adrenergic receptor) antibodies that have been explored both in humans and in experimental models [3] [4] [5] .
It has been demonstrated that T. cruzi B13 antigen promotes T cell cross-reactive responses due to sequence homology of part of this protein with a hexapeptide belonging to human cardiac myosin heavy chain 3 . Furthermore, these antibodies were present in patients with severe CCHD but rarely detectable in asymptomatic ones 6 .
As regards anti-p2β antibody, this cross-reacts against the second extracellular loop of the β1 adrenergic receptor that bears similarity to specific antigenic epitopes on parasitic ribosomal proteins p2β and P0 [7] [8] [9] [10] . Experimental studies have shown that these autoantibodies exert an agonistic effect on the β1AR inducing myocyte apoptosis, increased heart chronotropism, and electrocardiographic alterations 8, [11] [12] [13] . Furthermore, Diez et al. have suggested that the presence of severe CCHD coexisted with higher levels of these antibodies 14 .
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Finally, anti-β1AR antibodies were observed in individuals with dilated cardiomyopathy. Similarly as anti-p2β, anti-β1AR also have shown in experimental models that cross-react with β1AR inducing the same effects 8, 9 . However, an association between anti-β1AR antibodies and the clinical presentation of Chagas disease has never been explored.
In view of the long asymptomatic period that characterizes chronic T. cruzi infection and the pathogenic role autoantibodies, we hypothesize that they might be suitable biomarkers for early recognition of chronic indeterminate subjects with higher risk of CCHD progression. In these patients, reinforcement of preventive actions (or even specific parasitic treatment) could be particularly considered.
Therefore, we conducted the present study to ascertain the relationship of anti-β1AR and antip2β antibodies with the clinical profile of CCHD patients. We also explored the interactions between these antibodies with previously studied anti-B13 in order to characterize their integrated classification performance for HF, as a first approach to their potential prognostic utility.
Materials and methods

Study population and subject evaluation
In this cross-sectional observational study, 155 T. cruzi-seropositive patients from Santa Fe, Argentina, were prospectively included. Most were born in rural endemic areas in the north of the country. 
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This article is protected by copyright. All rights reserved. largement was associated with <45% ejection fraction and/or <25% of fractional shortening. Regarding HF treatment, it was specially assessed whether the patient had been taking β1-selective blockers at least for the 6 previous months at doses ranging from 5 to 10 mg/day for bisoprolol or 50 to 100 mg/day for atenolol.
The following exclusion criteria were considered: a) previously known coronary artery disease, or coronary artery disease equivalents such as diabetes mellitus or peripheral arterial disease; b) history of other cardiac diseases; c) systemic complaints; and d) previous or present treatment with anti-T. cruzi compounds or immunosuppressive drugs.
Written consent was obtained from all patients after they had been fully informed about the characteristics of the study. This research protocol was approved by the Ethics Review Board of J. B.
Iturraspe Hospital and National University of the Littoral. The procedures followed the ethical standards given in 1964 Declaration of Helsinki and its later amendments.
Proteins production and purification
For obtaining proteins used as coating antigens, Escherichia coli BL21(DE3) cells bearing the plasmidic constructions pET-32a/B13 or pET-32a/p2b, respectively, were grown overnight in LB medium, supplemented with 0.1 mg/ml ampicillin at 37 o C with agitation. Protein expression was induced in 1 mM isopropyl-β-D-thiogalactopyranoside and was purified with a Ni-nitrilotriacetic acid Sepharose column (GE Healthcare, UK) 18, 19 . 
The H26R peptide (H-W-W-R-A-E-S-D-E-
A-R-R-C-Y-N-D-P-K-C-C-D-F-V-T-N-R-C),
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Assessment of autoantibodies
Serum samples from patients were stored at -80°C until they were used for the measurement of antibodies against p2β, B13 and β1AR by specific immunoassays (ELISA) as previously described technique [18] [19] [20] . For assay standardization, results were expressed as an Index of Optical Density (IOD) of the sample in relation to the negative control (mean+2DS); an IOD ≤1 was considered negative.
Statistical analysis
Data were analyzed with MedCalc 12.2.1 (MedCalc Software, Belgium) and Graph Pad 5.03 (GraphPad software, USA). Normally distributed continuous variables are expressed as means ± SD.
Chi-square or Fisher's exact tests were used for comparing categorical variables, whereas Student's non-paired T test or a one-way ANOVA (Student-Newman-Keuls test for all pairwise comparisons), as considered appropriate, were used to compare means. Non-parametric tests were employed for comparison provided continuous variables not normally distributed. Pearson's correlation coefficient and adjusted R 2 were determined for estimating the association between two quantitative variables.
The association of the variables with the presence of symptoms and diagnosis of systolic HF was assessed. A multiple binary logistic regression model step-forward was performed combining variables that where both univariate and multivariate correlated to HF. Then we applied the bootstrap method in order to make an internal validation of the model in half of the sampled individuals. In addition, we plotted the discriminating capacity of the antibody levels to predict this endpoint in a Receiver Operating Characteristic (ROC) curve. In all cases, a p value < 0.05 was considered significant.
Results
Clinical profile and antibody status
Clinical features and humoral immune response to the studied antigens of the sampled CCHD individuals and controls are summarized in Table 1 . Symptomatic patients (CCHD stage II and III) presented increased levels of anti-β1AR and anti-B13. Positivity for anti-β1AR (IOD >1) was also associated with symptomatic CCHD stages (p<0.0001). On the other hand, as depicted in the table, antip2β IOD did not differ significantly among these categories. All control patients were negative for the above mentioned antibodies.
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ECG and ecocardiography findings
The most common alterations on ECG were left anterior fascicular block with right bundle branch block (n=32), atrial fibrillation (n=18), right bundle branch block (n=11) and right bundle branch block with atrial fibrillation (n=9). While anti-p2β IOD did not show variations, both left anterior fascicular block with right bundle branch block and right bundle branch block with atrial fibrillation, were associated with higher IOD of anti-β1AR and anti-B13 (p=0.02).
Antibody levels according to different echocardiographic findings are displayed in Table 2 . Individuals with dilated CCHD and reduced ejection fraction showed increased anti-B13 and anti-β1AR
antibodies as represented in Figure 1 . Again, anti-p2β levels remained similar between CCHD groups.
Diagnostic performance in patients with heart failure
We applied a binary logistic regression model step-forward to predict dilated cardiomyopathy associated with systolic heart failure employing the variables previously related to this outcome i.e., age, IOD of anti-B13, IOD of anti-β1, and hypertension. As stated above, levels of anti-P2β were excluded, as were other potential confounding variables (i.e., smoking, sex) due to an insignificant bivariate association. The analysis revealed that anti-β1, anti-B13 and age contributed significantly to the prediction of this outcome ( 
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Discussion
Cellular and humoral immune responses constitute intermingled pathological mechanisms dealing
with the visceral compromise in T. cruzi infection [21] [22] . It has been argued that autoimmune response, due to bystander or molecular mimicry between host and parasite proteins, plays a pathogenic role in the development of CCHD 3, 23 . In this regard, as a first approach, our study aimed to ascertain the levels of antibodies induced by T. cruzi regarding pathological clinical manifestations and their potential diagnostic performance in discriminating asymptomatic patients from those with severe forms of the disease.
Regarding anti-p2β, Diez et al suggested that the presence of severe CCHD coexisted with higher levels of these antibodies 14 . Conversely, in our study with a larger sample of individuals per group, this association was not found since anti-p2β antibodies did not differ significantly among the CCHD stages. We have previously described that intake of cardio selective β-blocker drugs to improve survival in systolic heart failure, as seen in individuals with Chagas disease, was related to higher levels of anti-p2β 19 . Possibly the increased anti-p2β levels of individuals with CCHD stage III reported by Diez et al. might have to do with this pharmacological treatment as these data was not analyzed in this paper. Beyond this issue, our study fails to support a pathological effect of anti-p2β antibodies on heart tissue. Novel prospective studies should be performed to clarify the controversy about the effects and utility of anti-p2β in Chagas disease.
Concerning anti-B13 antibodies, Tibbetts et al reported that infection by T. cruzi may induce a myosin antigen-specific autoantibody associated with chronic inflammatory cardiomyopathy 24 . As well as promoting T cell cross-reactive responses against human cardiac myosin heavy chain, anti-
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B13 is a well-documented serological test, which might be used as an earlier sera marker of response to anti T. cruzi treatment in chronic Chagas disease 25 . Cunha-Neto et al observed the presence of cardiac myosin-B13 cross-reactive antibodies in Chagas patients with heart failure 6 . Confirming and extending our observations 26 , increased anti-B13 titers are also seen in patients with echocardiographic diagnosis of systolic heart failure. Analysis by means of the logistic regression model confirms that anti-B13 can be regarded as a predictor of chronic Chagas heart disease.
Anti-β1AR was first described several years ago in an experimental model of Chagas disease . Several studies have proven their agonist effect on the β1AR inducing heart rhythm disturbances and left ventricular dysfunction in murine models 9, 10, 28 . However, in the work performed by Talvani et al, in which all T. cruzi-infected individuals had anti-β1AR antibodies no association between their levels and clinical manifestations was found 29 . Conversely, the study by Wallukat et al, recruiting a larger sample of individuals serologically positive for T. cruzi, showed that most asymptomatic individuals were anti-β1AR negative; whereas all cases with Chagas cardiomyopathy had positive levels of anti-β1AR 30 . However, they did not explore whether anti-β1AR levels showed a relationship with the degree of myocardial compromise.
In this regard, the main contribution of our work is to provide a more extensive data on the relationship between increased anti-β1AR and anti-B13 antibodies with CCHD. As commented, both autoantibodies may be helpful in early identification of asymptomatic individuals at risk of developing severe CCHD. In addition, it would be interesting to include them in more complex models employing other independent inflammation and cardiac-damage markers reported recently (i.e., T. cruzi parasitemia by RT-PCR, NT-proBNP) 31 .
Noteworthy is the fact that given the slow clinical progression of Chagas disease, even over decades, it was necessary to begin with a cross-sectional design as an initial attempt to assess the implications of these possible CCHD progression markers. We tried to achieve a significant sample size for a better study power, constituting a central contribution of the present work in relation to other studies in the literature.
Present studies should be expanded to other endemic scenarios to ultimately validate the usefulness of anti-β1AR and anti-B13 antibodies as an additional tool allowing a better control of at-risk patients, especially younger ones.
This was a single-center study and due to its design, we cannot extend our results to what happens in the evolution of the disease regarding antibody titers as patients change their CCHD stage. A longitudinal follow-up approach is necessary to confirm our findings.
Conclusions
In summary, our results suggest a significant association of anti-β1AR and anti-B13 antibodies with severe symptomatic Chagas heart disease. In addition, both estimations showed to be potential heart failure predictors by the regression model. Also, anti-β1AR and anti-B13 antibodies seem suitable for further validation in an prospective cohort. 
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